Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD

Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreno, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q Zhou, Willemijn Rijnink, Hala Alshammary, Nicholas Borcherding, Ana Gonzalez Reiche, Komal Srivastava, Emilia Mia Sordillo, Harm van Bakel, The Personalized Virology Initiative, Jackson S. Turner, Goran Bajic, View ORCID ProfileViviana Simon, Ali H. Ellebedy, Florian Krammer
doi: https://doi.org/10.1101/2021.03.07.21253098
Fatima Amanat
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
2Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahima Thapa
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tinting Lei
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaza M. Sayed Ahmed
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel C. Adelsberg
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan Manuel Carreno
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shirin Strohmeier
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aaron J. Schmitz
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Zafar
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julian Q Zhou
4AbCellera Biologics Inc., Vancouver, BC V5Y 0A1, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willemijn Rijnink
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hala Alshammary
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Borcherding
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Gonzalez Reiche
5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Komal Srivastava
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emilia Mia Sordillo
6Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harm van Bakel
5Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029
7Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jackson S. Turner
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Goran Bajic
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: goran.bajic@mssm.edu viviana.simon@mssm.edu ellebedy@wustl.edu florian.krammer@mssm.edu
Viviana Simon
9The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
10Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Viviana Simon
  • For correspondence: goran.bajic@mssm.edu viviana.simon@mssm.edu ellebedy@wustl.edu florian.krammer@mssm.edu
Ali H. Ellebedy
3Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, 63110
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: goran.bajic@mssm.edu viviana.simon@mssm.edu ellebedy@wustl.edu florian.krammer@mssm.edu
Florian Krammer
1Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: goran.bajic@mssm.edu viviana.simon@mssm.edu ellebedy@wustl.edu florian.krammer@mssm.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Summary

In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast derived mAbs from subjects who received SARS-CoV-2 spike mRNA vaccine. Polyclonal antibody responses in vaccinees were robust and comparable to or exceeded those seen after natural infection. However, that the ratio of binding to neutralizing antibodies after vaccination was greater than that after natural infection and, at the monoclonal level, we found that the majority of vaccine-induced antibodies did not have neutralizing activity. We also found a co-dominance of mAbs targeting the NTD and RBD of SARS-CoV-2 spike and an original antigenic-sin like backboost to seasonal human coronaviruses OC43 and HKU1 spike proteins. Neutralizing activity of NTD mAbs but not RBD mAbs against a clinical viral isolate carrying E484K as well as extensive changes in the NTD was abolished, suggesting that a proportion of vaccine induced RBD binding antibodies may provide substantial protection against viral variants carrying E484K.

Competing Interest Statement

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon is also listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. Ali Ellebedy has consulted for InBios and Fimbrion Therapeutics (before 2021) and is currently a consultant for Mubadala Investment Company. The Ellebedy laboratory received funding under sponsored research agreements that are unrelated to the data presented in the current study from Emergent BioSolutions and from AbbVie.

Funding Statement

This work was partially funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051, NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C and HHSN272201400006C), NIAID grants U01AI141990 and U01AI150747, by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors. J.S.T. was supported by NIAID 5T32CA009547.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Mount Sinai Hospital Institutional Review Board

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data is available upon reasonable request from the corresponding authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 09, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreno, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q Zhou, Willemijn Rijnink, Hala Alshammary, Nicholas Borcherding, Ana Gonzalez Reiche, Komal Srivastava, Emilia Mia Sordillo, Harm van Bakel, The Personalized Virology Initiative, Jackson S. Turner, Goran Bajic, Viviana Simon, Ali H. Ellebedy, Florian Krammer
medRxiv 2021.03.07.21253098; doi: https://doi.org/10.1101/2021.03.07.21253098
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target both the NTD and the RBD
Fatima Amanat, Mahima Thapa, Tinting Lei, Shaza M. Sayed Ahmed, Daniel C. Adelsberg, Juan Manuel Carreno, Shirin Strohmeier, Aaron J. Schmitz, Sarah Zafar, Julian Q Zhou, Willemijn Rijnink, Hala Alshammary, Nicholas Borcherding, Ana Gonzalez Reiche, Komal Srivastava, Emilia Mia Sordillo, Harm van Bakel, The Personalized Virology Initiative, Jackson S. Turner, Goran Bajic, Viviana Simon, Ali H. Ellebedy, Florian Krammer
medRxiv 2021.03.07.21253098; doi: https://doi.org/10.1101/2021.03.07.21253098

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (551)
  • Anesthesia (135)
  • Cardiovascular Medicine (1751)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (656)
  • Epidemiology (10790)
  • Forensic Medicine (8)
  • Gastroenterology (585)
  • Genetic and Genomic Medicine (2939)
  • Geriatric Medicine (287)
  • Health Economics (532)
  • Health Informatics (1921)
  • Health Policy (833)
  • Health Systems and Quality Improvement (744)
  • Hematology (291)
  • HIV/AIDS (628)
  • Infectious Diseases (except HIV/AIDS) (12508)
  • Intensive Care and Critical Care Medicine (687)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2789)
  • Nursing (151)
  • Nutrition (432)
  • Obstetrics and Gynecology (556)
  • Occupational and Environmental Health (597)
  • Oncology (1460)
  • Ophthalmology (443)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (380)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (363)
  • Primary Care Research (336)
  • Psychiatry and Clinical Psychology (2635)
  • Public and Global Health (5349)
  • Radiology and Imaging (1007)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (725)
  • Rheumatology (329)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)